Latigo prices $345.6 million IPO at $18 a share

Latigo priced its IPO at $18 a share for $345.6 million, one of the largest biotech raises of the year and enough capital to push its non-opioid painkiller against Vertex's head start. Goldman Sachs, Jefferies, Leerink and Guggenheim ran the books.

Biotech IPO revised, narrow price band signals measured appetite

Latigo Biotherapeutics revised its IPO terms in an amended S-1 filing, pricing 16 million shares at $16 to $18 apiece for a $272 million raise that will fund its non-opioid pain treatment pipeline targeting Vertex's turf.

Pain relief biotech Latigo filed to go public as non-opioid painkillers become the race to watch on Wall Street, backed by Goldman Sachs and Jefferies.